Nohui Health receives $30 million E-round financing to complete large-scale prospective multi-center clinical trial of China's first early cancer screening product ahead of schedule

Guide: Nohui Health Financing has been successful again, and early cancer screening has attracted much attentionon July 10,, Nohuco Health, China's first bio-high-tech company focused on early cancer screening, announced the completion of a $30 million E-round financing, led by Rock Springs Capital, led by Orbi Capital, Lilly Asia Fund (LAV), Cortmoran Asset Management, China Resources Capital, Octagon Capital and veteran shareholder Qiming VenturesTo date, Nohuco Health has received the continued attention of the world's leading venture capital, top biohealth funds and long-term investment institutions, with a total investment of more than $160 million, making it the most popular company for investors in cancer screeningNohui Health completed the E round of financing, favored by international long-term investors
Nohui Health was founded in 2013, creating china's colorectal cancer early screening marketIts independent research and development of "non-invasive multi-target fecal FIT-DNA joint detection" products - Chang Weiqing ® is China's first early screening products for bowel cancerAfter Exact Sciences, the U.Scancer early screening benchmark company, Nohui Health became the second company in the world to complete large-scale prospective multicenter clinical trials of early cancer screening products in ChinaUnder the guidance and supervision of the State Drug Administration, the trial was officially launched in September 2018, jointly covering eight large tertiary hospitals across the country, with a cumulative total of nearly 6,000 cases, and the submission of all clinical data was completed by early 2020Norhui Health independent research and development of "non-invasive multi-target fecal FIT-DNA joint detection" products - Chang Weiqing ® is China's first early screening products for bowel cancer
this round of financing will be used to consolidate the scale expansion of its main cancer early screening products, accelerate the development of new products, clinical research and market transformation, practice innovative diversified market strategy, to create Nohui Health as "China's cancer early screening first brand" core competitivenessCancer home early screening has been widely recognized by the community, which will become one of the most convenient means of effective prevention of cancer, Nohui Health, to accelerate the implementation of the "Healthy China 2030 Planning Outline" of the national strategy of early diagnosis and treatment of cancer" Nohui Health set up 7 years, do not forget the first heart, a forward, always focus on high-risk cancer home early screening this thingNohui Health can continue to lead the Chinese cancer early screening market, we sincerely thank investors for their supportZhu Yeqing, co-founder and CEO of Nohui Health, said: "Successful financing is based on norresis's core technical barriers with independent intellectual property rights and investor recognition of the Nouhui team, which also helps us to better focus on the company's long-term development strategy." Our mission is to do a good job in China's high-risk cancer home early screening, so that cancer prevention and control pass forward, the center of gravity, change the life trajectory of China's cancer high-risk groups, to help them truly achieve early screening, early diagnosis and early treatment, thereby reducing the mortality and morbidity of cancer in China"
" We appreciate The Company's culture of Nordse Health's down-to-earth, thick hair, and sincerely congratulate Noble Health on its landmark success in large-scale clinical trials "We're always looking for the most innovative variables in the world," says Mark Bussard, managing partner at Rock Springs Capital in the US Biotechnology has become an important driver of changing the world and human life With its huge population base and sustained economic growth, China is bound to become one of the most explosive health care markets "
" We firmly support Nohui Health as a leader in the cancer screening market in China Ms Wang Wei, Managing Director of OrbiMed Asia, said, "Nohui Health's first concept of early screening for cancer is an absolute leader in the market." We are very much looking forward to Norohui Health's full range of products, for China's cancer risk groups to bring better choices and help "
Rock Springs Capital Rock Springs Capital is a world-leading investment firm focused on corporate investment strategies in healthcare and related areas ororbiMed OrbiMed, an investment firm focused on the healthcare industry with more than $14 billion in assets under management, covering start-up, long-term, mature and post-IPO Obo Capital brings the resources and experience it needs to build a world-class healthcare company and is committed to being a long-term partner for excellence Lilly Asia Fund (LAV) Lilly Asia Fund (LAV) was established in 2008 as a leading venture fund focused on investments in the life sciences and healthcare industries, with offices in Shanghai, China, Hong Kong, China and Silicon Valley in the United States Lilly Asia is committed to being a reliable partner for outstanding entrepreneurs in their quest for smart capital to create great companies that can overcome disease and improve human health with breakthrough products about Cormorant Asset Management
Cormorant Asset Management, a registered investment advisor to the Securities and Exchange Commission based in Boston, Massachusetts, has been providing investment advisory services since March 2013 and currently manages more than $2 billion in assets, primarily in healthcare and life sciences Managing The Cormorant Global Healthcare MasterFund, LP and Cormorant Private Healthcare Fund II, LP's long-term investments in healthcare and life sciences companies on China Resources Zhengda Life Sciences Fund China Resources Zhengda Life Sciences Fund is a private equity fund jointly launched by China Resources Group and Thailand Zhengda Group, focusing on investing in early and growing enterprises in the life sciences sector, with a $300 million fund in the first phase The Fund invests in innovations in the global life sciences sector to meet the needs of Chinese patients for innovative products, technologies and services The Fund Investment Team has extensive management and investment experience in the field of health, helping the invested enterprises to add value to their Business in China about Octagon Capital
Octagon Investments Master Fund LP ('Octagon Investments') is an exempted limited partnership established under Cayman Islands law and is an investment fund Octagon Capital Advisors LP ("Octagon Capital") is a limited partnership registered in Delaware and a registered investment advisor to the Securities and Exchange Commission that manages Octagon Investments investments Founded in 2019, Octagon Capital is a multi-stage investment management company focused on the biomedical industry Octagon Capital invests in both public and private equity and seeks to be a long-term investment partner for biomedical companies Octagon Capital manages capital from institutions around the world, including university endowments, non-profit foundations, family offices and established asset management companies on Qiming Ventures Qiming Ventures was established in 2006 and has offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area At present, Qiming Ventures manages nine US dollar funds and five RMB funds with total assets under management of more than US$5.3 billion Since its inception, it has focused on investing in early and long-term excellence in industries such as TMT and Healthcare up to now, Qiming Ventures has invested in more than 350 high-growth innovative enterprises, including more than 110 in the United States NYSE, NASDAQ, Hong Kong Stock Exchange, Taiwan Counter BuyIng Center, SSE, Shenzhen Stock Exchange and other exchanges listed, more than 30 enterprises have become the industry recognized unicorns and super unicorn enterprises